Savara (SVRA) Surges 3.32% on Analyst Upgrade and Positive Phase 3 Trial Data

Savara (SVRA) surged 3.32% on Wednesday, marking its third consecutive day of gains with a cumulative rise of 4.59% over the past three days. The stock hit an intraday high of 5.14% above its previous close, reaching its highest level since September 2025. This upward momentum reflects investor confidence in the company’s recent strategic and clinical advancements.

A key catalyst for the rally is an upgraded analyst rating, with a prominent research firm elevating its recommendation to “Strong Buy” and increasing its price target to $8 per share. The revision underscores optimism around Savara’s lead candidate, molgramostim nebulizer solution, which is in late-stage development for autoimmune pulmonary alveolar proteinosis (aPAP). Positive Phase 3 trial data from the IMPALA-2 study, set for presentation at an international respiratory conference and publication in a leading medical journal, has bolstered market sentiment. Analysts highlight the drug’s potential to address aPAP’s underlying pathology, a critical differentiator in a treatment gap.

Recent updates to patient prevalence estimates further support the stock’s trajectory. New U.S. health claims data revealed a 50% increase in the estimated autoimmune PAP patient population, now approximating 5,500 individuals. This growth signals rising awareness and diagnosis rates, expanding the potential market for molgramostim if approved. Savara’s leadership emphasized the data’s role in strengthening commercial viability, as a larger patient pool enhances unmet medical need and long-term revenue prospects.

Regulatory progress is another driver. The company plans to resubmit its Biologics License Application (BLA) for molgramostim to the FDA in December 2025, seeking Priority Review. This application benefits from multiple designations, including Fast Track and Orphan Drug, which expedite regulatory pathways. Additionally, the drug has received international designations in the UK, reinforcing its global development strategy. The recent publication of Phase 3 trial results in a high-impact journal is expected to strengthen the BLA submission and regulatory approval prospects.

Financially, Savara has secured non-dilutive financing of up to $200 million, ensuring liquidity for regulatory submissions and commercialization efforts. Despite a 2025 loss, analysts project $8.24 million in 2026 revenue, driven by molgramostim’s development. The company’s operational focus on outsourcing capital-intensive processes and refining its BLA data package positions it to meet key milestones efficiently. Combined with a seasoned management team and a robust pipeline, these factors reinforce the stock’s appeal as a speculative but high-reward biotech play.